Compare Gigacloud Technology Inc (GCT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs BIO-TECHNE Corp — how do they compare? Gigacloud Technology Inc trades at $55.75 (market cap $2.02B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 5.6× Gigacloud Technology Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 21 Days and BIO-TECHNE Corp for 63 Days on average.
| GCT | TECH | |
|---|---|---|
Market Cap | $2.02B | $11.36B |
Volume | 1,020,985 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $56.42 | $72.61 |
52-Week Low | $25.46 | $43.31 |
Typical Hold Time | 21 Days | 63 Days |
Enterprise Value | $2.14B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GCT trades at $55.96, up 2.19% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, 10.65% net margins, and 27.6% YoY revenue growth in Q2 2026. Recent news highlights institutional interest and European expansion driving optimism.
The outlook remains positive with 66.7% analyst buy ratings and a $32.50 consensus target, though RSI levels suggest potential near-term consolidation. Key risks include insider selling activity and market volatility, but strong cash flow generation and disciplined expansion support long-term growth prospects.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
